Genelux Corporation (GNLX) News
Follow Genelux Corporation (GNLX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically De
A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy ---- This patient also a
COMMODITIES | Sep 09, 2026, 08:03 PM UTC
L
GNLX - Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemic
GNLX - Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
COMMODITIES | Sep 09, 2026, 08:01 PM UTC
L
Genelux reports second-quarter financial results and business updates
Genelux Corporation reports second-quarter financial results and provides business updates, according to the company announcement.
EARNINGS | Aug 13, 2026, 08:20 PM UTC
L
Genelux Announces Publication Of Translational And Clinical Findings From Phase 1b/2 VIRO-15 Trial Of Olvi-Vec-Primed Immunochemotherapy In
Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial - - Data demonstrate Olvi-Vec–mediated modulation of th
COMMODITIES | Jun 30, 2026, 12:02 PM UTC